You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M‐induced resistance
|
|---|---|
| Published in |
Cancer Communications, July 2015
|
| DOI | 10.1186/s40880-015-0029-3 |
| Pubmed ID | |
| Authors |
Xiao Xu |
| Abstract |
Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance. Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non-small cell lung cancer patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 22% |
| Student > Master | 4 | 15% |
| Lecturer | 3 | 11% |
| Student > Doctoral Student | 3 | 11% |
| Professor > Associate Professor | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 6 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 22% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Nursing and Health Professions | 2 | 7% |
| Chemistry | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 7 | 26% |